IPP Bureau
Trial milestone sparks hope for first long-term gastroparesis treatment
By IPP Bureau - March 19, 2026
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
Zydus and Torrent Pharma to co-market Semaglutide injection in India
By IPP Bureau - March 19, 2026
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
Strides acquires generic brands from Sandoz to boost Africa business
By IPP Bureau - March 19, 2026
The initial consideration for the transaction is US$ 12 million
Mankind Pharma acquires Rivotril brand for India
By IPP Bureau - March 19, 2026
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students
By IPP Bureau - March 19, 2026
SPARK has extended its influence to an additional 9.47 million students worldwide
Lupin Manufacturing Solutions announces expansion of Dabhasa facility
By IPP Bureau - March 19, 2026
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
By IPP Bureau - March 18, 2026
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
By IPP Bureau - March 18, 2026
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
PsiQuantum joins forces with Japan’s National Cancer Center to revolutionize cancer research with quantum computing
By IPP Bureau - March 18, 2026
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
Zydus, Lupin join forces to expand access to semaglutide in India
By IPP Bureau - March 18, 2026
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option
By IPP Bureau - March 17, 2026
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers
By IPP Bureau - March 17, 2026
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Allergan Aesthetics unveils ‘Skin Quality Index’ to close gap between patients & doctors
By IPP Bureau - March 17, 2026
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema
By IPP Bureau - March 17, 2026
The company announced positive topline data from the Phase 3 ADorable-1 trial
Merck doubles down on cardio-pulmonary breakthroughs
By IPP Bureau - March 17, 2026
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
